117 related articles for article (PubMed ID: 10068364)
1. A novel antimicrobial agent joins the battle against resistant bacteria.
Moellering RC
Ann Intern Med; 1999 Jan; 130(2):155-7. PubMed ID: 10068364
[No Abstract] [Full Text] [Related]
2. Linezolid approval brings new treatment option for resistant bacteria.
Am J Health Syst Pharm; 2000 Jun; 57(11):1018. PubMed ID: 10876739
[No Abstract] [Full Text] [Related]
3. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials.
Dresser LD; Rybak MJ
Pharmacotherapy; 1998; 18(3):456-62. PubMed ID: 9620097
[TBL] [Abstract][Full Text] [Related]
4. An update on the oxazolidinone antibiotics.
Abdel-Rahman SM; Kearns GL
Pediatr Infect Dis J; 1999 Dec; 18(12):1101-2. PubMed ID: 10608633
[No Abstract] [Full Text] [Related]
5. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to the novel oxazolidinones eperezolid (PNU-100592) and linezolid (PNU-100766).
Hoppe JE
J Chemother; 1999 Jun; 11(3):220-1. PubMed ID: 10435686
[No Abstract] [Full Text] [Related]
6. [A new antibacterial agent can stop resistance development. Expectations are connected to linezolid, an oxazolidinone with a new pharmacological action].
Sköld O
Lakartidningen; 1999 Sep; 96(37):3866-7. PubMed ID: 10522087
[No Abstract] [Full Text] [Related]
7. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin.
Noskin GA; Siddiqui F; Stosor V; Kruzynski J; Peterson LR
Clin Infect Dis; 1999 Mar; 28(3):689-90. PubMed ID: 10194104
[No Abstract] [Full Text] [Related]
8. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.
Cynamon MH; Klemens SP; Sharpe CA; Chase S
Antimicrob Agents Chemother; 1999 May; 43(5):1189-91. PubMed ID: 10223934
[TBL] [Abstract][Full Text] [Related]
9. Oxazolidinones: a review.
Diekema DI; Jones RN
Drugs; 2000 Jan; 59(1):7-16. PubMed ID: 10718097
[TBL] [Abstract][Full Text] [Related]
10. Linezolid, critical characteristics.
Hamel JC; Stapert D; Moerman JK; Ford CW
Infection; 2000; 28(1):60-4. PubMed ID: 10744479
[No Abstract] [Full Text] [Related]
11. New antibiotics for gram positive infections: linezolid and combination quinapristin/dalfopristin.
MacConnachie AM
Intensive Crit Care Nurs; 1999 Aug; 15(4):239-41. PubMed ID: 10786510
[TBL] [Abstract][Full Text] [Related]
12. In vitro activities in new oxazolidinone antimicrobial agents against enterococci.
Eliopoulos GM; Wennersten CB; Gold HS; Moellering RC
Antimicrob Agents Chemother; 1996 Jul; 40(7):1745-7. PubMed ID: 8807077
[TBL] [Abstract][Full Text] [Related]
13. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.
Chien JW; Kucia ML; Salata RA
Clin Infect Dis; 2000 Jan; 30(1):146-51. PubMed ID: 10619743
[TBL] [Abstract][Full Text] [Related]
14. Methicillin-resistant Staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): new treatment options for infections due to resistant organisms.
Antony SJ; Bitter KM; Moreland T; Raudales F; Diaz-Luna H
Clin Infect Dis; 1999 Nov; 29(5):1341-2. PubMed ID: 10524997
[No Abstract] [Full Text] [Related]
15. MICs of oxazolidinones for Rhodococcus equi strains isolated from humans and animals.
Bowersock TL; Salmon SA; Portis ES; Prescott JF; Robison DA; Ford CW; Watts JL
Antimicrob Agents Chemother; 2000 May; 44(5):1367-9. PubMed ID: 10770781
[TBL] [Abstract][Full Text] [Related]
16. Activity of linezolid against multi-resistant gram-positive bacteria from diverse hospitals in the United Kingdom.
Johnson AP; Warner M; Livermore DM
J Antimicrob Chemother; 2000 Feb; 45(2):225-30. PubMed ID: 10660506
[TBL] [Abstract][Full Text] [Related]
17. Linezolid breakpoints.
European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Clin Microbiol Infect; 2001 May; 7(5):283-4. PubMed ID: 11422259
[No Abstract] [Full Text] [Related]
18. Tedizolid for the management of human infections: in vitro characteristics.
Locke JB; Zurenko GE; Shaw KJ; Bartizal K
Clin Infect Dis; 2014 Jan; 58 Suppl 1():S35-42. PubMed ID: 24343830
[TBL] [Abstract][Full Text] [Related]
19. [Linezolid (Zyvox)--a novel antibacterial agent for treatments of multidrug-resistant infections].
Blatun LA
Antibiot Khimioter; 2002; 47(2):38-46. PubMed ID: 12087723
[No Abstract] [Full Text] [Related]
20. Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: novel analogs of linezolid.
D'Andrea S; Zheng ZB; Denbleyker K; Fung-Tomc JC; Yang H; Clark J; Taylor D; Bronson J
Bioorg Med Chem Lett; 2005 Jun; 15(11):2834-9. PubMed ID: 15911264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
